scholarly journals Atherosclerosis [Dhamani Pratichaya] in View of Ayurved

2021 ◽  
Vol 04 (11) ◽  
Author(s):  
Dr. Sangram Mane ◽  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Treatment Regimen ◽  
Lifestyle Changes ◽  
Integrative Approach ◽  
Early Interventions ◽  
Appropriate Use ◽  
Disease Condition ◽  
Suitable Treatment ◽  
Diet And Lifestyle

Atherosclerosis is a disease condition leading to serious consequences such as ischemic heart disease and stroke. Diet and lifestyle changes are most important for the management of this condition. In this review Ayurvedic understanding of this condition is reported. It is termed as Dhamani pratichay by Charak Samhita and Ashtang Sangraha, as a disease of kapha dosha. Appropriate use of a suitable treatment regimen of kapha dosha is helpful to prevent and combat this disease. Nidanparivarjan [discontinuation of causative food and lifestyle] is necessary to prevent blockages. The specific Ayurvedic etiological factors [hetu], early interventions to prevent the condition have been reviewed in this paper. In severe cases, integrative approach must be used.

scholarly journals Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview

2021 ◽  
Author(s):  
Qais Radaideh ◽  
Nicolas W. Shammas ◽  
Ghassan E. Daher ◽  
Rayan Jo Rachwan
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Medical Therapy ◽  
Coronary Revascularization ◽  
Coronary Intervention ◽  
Outpatient Setting ◽  
Lifestyle Changes ◽  
Ischemic Heart ◽  
Risk Factor Modification ◽  
Stable Ischemic Heart Disease

AbstractStable ischemic heart disease (SIHD) affects approximately 10 million Americans with 500,000 new cases diagnosed each year. Patients with SIHD are primarily managed in the outpatient setting with aggressive cardiovascular risk factor modification via medical therapy and lifestyle changes. Currently, this approach is considered as the mainstay of treatment. The recently published ISCHEMIA trial has established the noninferiority of medical therapy in comparison to coronary revascularization in patients with moderate to severe ischemia. Percutaneous coronary intervention is currently recommended for patients with significant left main disease, large ischemic myocardial burden, and patients with severe refractory angina despite maximal medical therapy.

scholarly journals Evaluation of 880 patients diagnosed with acute pancreatitis according to the Revised Atlanta Classification: A single-center experience

2020 ◽  
Vol 66 (5) ◽  
pp. 643-648
Author(s):  
Omer Burcak Binicier ◽  
Hatice Cilem Binicier
Keyword(s):  
Acute Pancreatitis ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Disease Severity ◽  
Demographic Data ◽  
Mortality Rates ◽  
Lifestyle Changes ◽  
Ischemic Heart ◽  
Single Center ◽  
Single Center Experience

SUMMARY OBJECTIVE The Revised Atlanta Classification (RAC) is increasingly used in the evaluation of patients diagnosed with acute pancreatitis (AP). In our study, we aimed to evaluate the etiology, disease severity, and mortality rates of patients diagnosed with AP in our center in the previous 6 years. METHODS Patients diagnosed with AP between 2013 and 2018 were evaluated. AP etiology, demographic data, disease severity, and mortality rates according to the RAC were evaluated. RESULTS A total of 880 patients were included in the study. Five hundred and eighteen (59%) patients were female and 362 (41%) were male. Regarding the etiology, 474 (53.9%) patients had biliary AP (BAP), 71 (8.1%) had hyperlipidemic AP (HAP), and 44 (5%) had alcoholic AP (AAP). According to the RAC, 561 (63.7%) patients were considered to be in the mild AP group (MAP), 268 (30.5%) in the moderately severe AP (MSAP), and 51 (5.8%) in the severe AP (SAP). The mortality rate was 4.8% in the MSAP group and 49% in the SAP group. Mortality was 2.3 times in patients over 65 years old and 3.7 times higher in patients with ischemic heart disease. CONCLUSIONS In our country, BAP is still the main etiology of acute pancreatitis. Over the years, we have seen a decrease in BAP and idiopathic AP cases, while there was an increase in HAP cases due to factors such as lifestyle changes and fatty nutrition. We found that mortality was associated with disease severity, advanced age (> 65 y), hypertension, and ischemic heart disease regardless of the etiology.

Antianginal Therapy for Stable Ischemic Heart Disease

2017 ◽  
Vol 22 (6) ◽  
pp. 499-510 ◽  
Author(s):  
Santosh K. Padala ◽  
Michael P. Lavelle ◽  
Mandeep S. Sidhu ◽  
Katherine P. Cabral ◽  
Doralisa Morrone ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
The United States ◽  
Lifestyle Changes ◽  
Ischemic Heart ◽  
Microvascular Angina ◽  
Pharmacologic Intervention ◽  
Stable Ischemic Heart Disease ◽  
Chronic Angina ◽  
Β Blockers

Chronic angina pectoris is associated with considerable morbidity and mortality, especially if treated suboptimally. For many patients, aggressive pharmacologic intervention is necessary in order to alleviate anginal symptoms. The optimal treatment of stable ischemic heart disease (SIHD) should be the prevention of angina and ischemia, with the goal of maximizing both quality and quantity of life. In addition to effective risk factor modification with lifestyle changes, intensive pharmacologic secondary prevention is the therapeutic cornerstone in managing patients with SIHD. Current guidelines recommend a multifaceted therapeutic approach with β-blockers as first-line treatment. Another important pharmacologic intervention for managing SIHD is nitrates. Nitrates can provide both relief of acute angina and can be used prophylactically before exposure to known triggers of myocardial ischemia to prevent angina. Additional therapeutic options include calcium channel blockers and ranolazine, an inhibitor of the late inward sodium current, that can be used alone or in addition to nitrates or β-blockers when these agents fail to alleviate symptoms. Ranolazine appears to be particularly effective for patients with microvascular angina and endothelial dysfunction. In addition, certain antianginal therapies are approved in Europe and have been shown to improve symptoms, including ivabradine, nicorandil, and trimetazidine; however, these have yet to be approved in the United States. Ultimately, there are several different medications available to the physician for managing the patient with SIHD having chronic angina, when either used alone or in combination. The purpose of this review is to highlight the most important therapeutic approaches to optimizing contemporary treatment in response to individual patient needs.

Sign in / Sign up

Export Citation Format

Share Document